A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

NCT02117024 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

66

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor Decision; strategic - based on changing treatment landscape

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Viagenpumatucel-L
DRUG: Metronomic Cyclophosphamide
DRUG: Physician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed)

Sponsor

Heat Biologics